shutterstock_2320390405_rafapress

5 December 2023Big PharmaLiz Hockley

US biotech wins review of rival’s endocrine patents after Vidal intervention

USPTO director remanded case back to PTAB after it denied post-grant review of Spruce patents | Judges determined likelihood of claims being unpatentable due to prior art and lack of written description.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Vidal overturns PTAB decision on pig vaccine patent

2 March 2023 Boehringer Ingelheim challenged university patent | Board must provide more details on ruling.

Vidal issues non-binding guidance on Fintiv denials

23 June 2022 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

More on this story

Biotechnology

Vidal overturns PTAB decision on pig vaccine patent

2 March 2023 Boehringer Ingelheim challenged university patent | Board must provide more details on ruling.

Vidal issues non-binding guidance on Fintiv denials

23 June 2022 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

More on this story

Biotechnology

Vidal overturns PTAB decision on pig vaccine patent

2 March 2023 Boehringer Ingelheim challenged university patent | Board must provide more details on ruling.

Vidal issues non-binding guidance on Fintiv denials

23 June 2022 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages